Epigenetic pathogenesis of cutaneous squamous cell carcinoma

Abstract

Sang Yingbing, Liang Junqin. Epigenetic pathogenesis of cutaneous squamous cell carcinoma[J]. Journal of International Oncology, 2020, 47(9): 569-572.

References22

[1]	Venables ZC, Nijsten T, Wong KF, et al. Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K.2013-15: a cohort study[J]. Br J Dermatol, 2019,181(3):474-482. DOI: 10.1111/bjd.17873. doi:10.1111/bjd.17873pmid:30864158
[2]	Stang A, Khil L, Kajüter H, et al. Incidence and mortality for cutaneous squamous cell carcinoma: comparison across three continents[J]. J Eur Acad Dermatol Venereol, 2019,33 Suppl 8: 6-10. DOI: 10.1111/jdv.15967. doi:10.1111/jdv.15318pmid:30811690
[3]	Umezono Y, Sato Y, Noto M, et al. Incidence rate of cutaneous squamous cell carcinoma is rapidly increasing in Akita Prefecture: urgent alert for super-aged society[J]. J Dermatol, 2019,46(3):259-262. DOI: 10.1111/1346-8138.14759. doi:10.1111/1346-8138.14759pmid:30614560
[4]	Hillen U, Leiter U, Haase S, et al. Advanced cutaneous squamous cell carcinoma: a retrospective analysis of patient profiles and treatment patterns—results of a non-interventional study of the DeCOG[J]. Eur J Cancer, 2018,96:34-43. DOI: 10.1016/j.ejca.2018.01.075. doi:10.1016/j.ejca.2018.01.075pmid:29665511
[5]	Ando M, Saito Y, Xu G, et al. Chromatin dysregulation and DNA methylation at transcription start sites associated with transcriptional repression in cancers[J]. Nat Commun, 2019,10(1):2415. DOI: 10.1038/s41467-019-09937-w. doi:10.1038/s41467-019-10557-7pmid:31142745
[6]	Li J, Hu WX, Luo SQ, et al. Promoter methylation induced epigene-tic silencing of DAZAP2, a downstream effector of p38/MAPK pathway, in multiple myeloma cells[J]. Cell Signal, 2019,60:136-145. DOI: 10.1016/j.cellsig.2019.04.012. doi:10.1016/j.cellsig.2019.04.012pmid:31034872
[7]	Hervás-Marín D, Higgins F, Sanmartín O, et al. Genome wide DNA methylation profiling identifies specific epigenetic features in high-risk cutaneous squamous cell carcinoma[J]. PLoS One, 2019,14(12):e0223341. DOI: 10.1371/journal.pone.0223341. doi:10.1371/journal.pone.0223341pmid:31860637
[8]	Yang Y, Wu R, Sargsyan D, et al. UVB drives different stages of epigenome alterations during progression of skin cancer[J]. Cancer Lett, 2019,449:20-30. DOI: 10.1016/j.canlet.2019.02.010. doi:10.1016/j.canlet.2019.02.010pmid:30771437
[9]	Tam S, Yao CMK, Amit M, et al. Association of immunosuppression with outcomes of patients with cutaneous squamous cell carcinoma of the head and neck[J]. JAMA Otolaryngol Head Neck Surg, 2019,146(2):128-135. DOI: 10.1001/jamaoto.2019.3751. doi:10.1001/jamaoto.2019.3751pmid:31804658
[10]	Jambusaria-Pahlajani A, Crow LD, Lowenstein S, et al. Predicting skin cancer in organ transplant recipients: development of the SUNTRAC screening tool using data from a multicenter cohort study[J]. Transpl Int, 2019,12:1259-1267. DOI: 10.1111/tri.13493.
[11]	Peters FS, Peeters AMA, Mandaviya PR, et al. Differentially methy-lated regions in T cells identify kidney transplant patients at risk for de novo skin cancer[J]. Clin Epigenetics, 2018,10:81. DOI: 10.1186/s13148-018-0519-7. doi:10.1186/s13148-018-0519-7pmid:29946375
[12]	Peters FS, Peeters AMA, van den Bosch TPP, et al. Disrupted regulation of serpinB9 in circulating T cells is associated with an increased risk for post-transplant skin cancer[J]. Clin Exp Immunol, 2019,197(3):341-351. DOI: 10.1111/cei.13309. doi:10.1111/cei.13309pmid:31059128
[13]	Gao X, Cheng Z, Yuan H, et al. K-Ras-PI3K regulates H3K56ac through PCAF to elevate the occurrence and growth of liver cancer[J]. J Cell Physiol, 2020,235(4):3905-3915. DOI: 10.1002/jcp.29284. doi:10.1002/jcp.v235.4pmid:31642074
[14]	Ichise T, Yoshida N, Ichise H. CBP/p300 antagonises EGFR-Ras-Erk signalling and suppresses increased Ras-Erk signaling-induced tumour formation in mice[J]. J Pathol, 2019,249(1):39-51. DOI: 10.1002/path.5279. doi:10.1002/path.5279pmid:30953353
[15]	McHugh A, Fernandes K, South AP, et al. Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity[J]. Oncotarget, 2018,9(29):20265-20281. DOI: 10.18632/oncotarget.24750. doi:10.18632/oncotarget.24750pmid:29755650
[16]	McHugh A, Fernandes K, Chinner N, et al. The identification of potential therapeutic targets for cutaneous squamous cell carcinoma[J]. J Invest Dermatol, 2020,140(6):1154-1165.e5. DOI: 10.1016/j.jid.2019.09.024. doi:10.1016/j.jid.2019.09.024pmid:31705877
[17]	Xu J, Meng Q, Li X, Yang H, et al. Long noncoding RNA MIR17HG promotes colorectal cancer progression via miR-17-5p[J]. Cancer Res, 2019,79(19):4882-4895. DOI: 10.1158/0008-5472.CAN-18-3880. doi:10.1158/0008-5472.CAN-18-3880pmid:31409641
[18]	Vidovic D, Huynh TT, Konda P, et al. ALDH1A3-regulated long non-coding RNA NRAD1 is a potential novel target for triple-negative breast tumors and cancer stem cells[J]. Cell Death Differ, 2020,27(1):363-378. DOI: 10.1038/s41418-019-0362-1. doi:10.1038/s41418-019-0362-1pmid:31197235
[19]	He K, Li WX, Guan D, et al. Regulatory network reconstruction of five essential microRNAs for survival analysis in breast cancer by integrating miRNA and mRNA expression datasets[J]. Funct Integr Genomics, 2019,19(4):645-658. DOI: 10.1007/s10142-019-00670-7. pmid:30859354
[20]	Gong ZH, Zhou F, Shi C, et al. miRNA-221 promotes cutaneous squamous cell carcinoma progression by targeting PTEN[J]. Cell Mol Biol Lett, 2019,24:9. DOI: 10.1186/s11658-018-0131-z. doi:10.1186/s11658-018-0131-zpmid:30891072
[21]	Sand M, Bechara FG, Sand D, et al. Expression profiles of long noncoding RNAs in cutaneous squamous cell carcinoma[J]. Epigenomics, 2016,8(4):501-518. DOI: 10.2217/epi-2015-0012. doi:10.2217/epi-2015-0012pmid:27067026
[22]	Yu GJ, Sun Y, Zhang DW, et al. Long non-coding RNA HOTAIR functions as a competitive endogenous RNA to regulate PRAF2 expression by sponging miR-326 in cutaneous squamous cell carcinoma[J]. Cancer Cell Int, 2019,19:270. DOI: 10.1186/s12935-019-0992-x. doi:10.1186/s12935-019-0992-xpmid:31649487

Epigenetic pathogenesis of cutaneous squamous cell carcinoma

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References22

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Zhang Junpeng, Yu Yanyan, Li Baosheng.Mechanism of lncRNA and circRNA regulating the sensitivity of radiotherapy and chemotherapy in esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2022, 49(3): 185-189.
[2]	Wang Pei, Cui Manli, Zhang Mingxin.Application of non-coding RNAs in early diagnosis of colorectal cancer[J]. Journal of International Oncology, 2021, 48(8): 502-506.
[3]	Deng Bo'er, Kong Weimin.Epigenetic research progress of endometrial cancer[J]. Journal of International Oncology, 2021, 48(3): 184-188.
[4]	He Miao, Fan Kui, Cao Fang.Epigenetics and drug resistance in lung cancer[J]. Journal of International Oncology, 2021, 48(10): 622-626.
[5]	Xiao Chang, Xin Yan.Research progress of non-coding RNA in gastric cancer[J]. Journal of International Oncology, 2019, 46(9): 553-557.
[6]	Zhang Fangyong, Wu Fan.Research progress on exosomederived noncoding RNAs in liquid biopsy of hepatocelluar carcinoma[J]. Journal of International Oncology, 2019, 46(6): 378-381.
[7]	Zhao Juan, Kang Xiaojing. Human telomerase reverse transcriptase and cutaneous malignant tumor[J]. Journal of International Oncology, 2019, 46(10): 634-637.
[8]	Li Zhi, Xu Jingkai, Zhang Bo.Mechanisms of long non-coding RNAs in tumors[J]. Journal of International Oncology, 2018, 45(4): 220-222.
[9]	An Liang, Li Jun, Chen Yuxiang, Fang Xiang.Analysis of correlation between RASSF2A gene methylation and colorectal cancer[J]. Journal of International Oncology, 2018, 45(2): 77-79.
[10]	ZHAO Yi, YAN Shan-Jun, WANG Qi-Zhi.Expression and mechanism of UCA1 in gastrointestinal tumors[J]. Journal of International Oncology, 2017, 44(2): 142-144.
[11]	Pan Haixia, Liang Liang, Ren Gang, Bai Yifeng.Expression and significance of long non-coding RNA RP11629B11.4 in triple negative breast cancer patients[J]. Journal of International Oncology, 2017, 44(12): 886-891.
[12]	Gu Shuming, Xu Min..Role of long non-coding RNA urothelial carcinoma associated antigen 1 as a competing endogenous RNA in the regulation of the initiation and progression of tumor[J]. Journal of International Oncology, 2017, 44(12): 911-913.
[13]	Li Wenqing, Hou Jinsong.Epigenetic regulation of epithelial-mesenchymal transition[J]. Journal of International Oncology, 2017, 44(12): 918-921.
[14]	ZHANG Kai-Li, YE Fang.Advances of epigenetics studys in malignant tumors[J]. Journal of International Oncology, 2016, 43(12): 915-917.
[15]	Zhao Yi, Zhang Xingxing, Xu Min.Expressions and roles of long non-coding RNA UCA1 in tumors[J]. Journal of International Oncology, 2015, 42(7): 519-521.